Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Management will be answering emailed questions from investors. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVI™, INCRELEX
Source: Eton Pharmaceuticals, Inc.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canada advocates buyers’ alliance to tackle critical minerals supply concentration
Air Products Falls 1.23% Despite Earnings Beat 430th in Trading Volume Amid Sector Headwinds
Agilent's Stock Climbs 0.74% as Trading Volume Crumbles 20.6% to Rank 442nd in Volume
IDEXX's Slight Earnings Miss Leads to 0.18% Decline, with $320M Trading Volume Placing 450th on March 3
Trending news
MoreCrypto prices
More
